Revenue segments as reported by the company.

Medical Devices

Specialty Pharmaceuticals

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Royalty expense

Amortization expense

Intangible asset impairment charges

Contingent consideration net expense (benefit)

Restructuring net charges (credits)

Litigation-related net charges (credits)

Gain on disposal of businesses and assets

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Boston Scientific

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment consists of technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979, and is headquartered in Marlborough, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Boston Scientific reports solid Q4 performance and eyes global growth

Boston Scientific's Q4 performance was solid, with growth across regions and business units.
Challenges include potential sales growth hurdles in Q1 2023 and headwinds from tough comps and market adjustments.
Opportunities lie in continued momentum in key business units, successful product launches, and global growth prospects.
The company remains focused on sustaining growth, expanding margins, and delivering double-digit adjusted EPS growth.

Boston Scientific surpasses Q1 expectations, eyes growth through Farapulse

Boston Scientific's Q1 '23 earnings call showcased strong performance, with exceeding revenue expectations and solid organic sales growth. The company's strategic focus on high-growth M&A, resolving supply constraints for Farapulse, and capital allocation priorities position it well for future growth. Challenges include potential earnings dilutive deals and addressing free cash flow conversion challenges.

Boston Scientific surpasses Q2 expectations, eyes margin expansion and innovation

Boston Scientific delivered a strong Q2 '23 performance, exceeding expectations with robust sales growth and improved adjusted EPS, driven by strong performance across key regions and business segments.
While facing challenges such as inflation impact and market dynamics, the company remains focused on opportunities for margin expansion, product innovation, and strategic acquisitions to drive future growth.
With a positive outlook for the coronary business, upcoming product launches, and a commitment to operational excellence, Boston Scientific aims to maintain its competitive edge and capitalize on market opportunities.
Anticipated results from trials, market potential for new products, and a focus on sustainable growth strategies position Boston Scientific for continued success and market leadership in the healthcare sector.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities ahead

Boston Scientific's Q3 2023 results exceeded expectations, with strong performance across regions and business units.
The company raised full-year guidance, expecting organic revenue growth of approximately 11% and adjusted EPS range of $1.99 to $2.02.
Challenges in the Neuromodulation business and cost impacts are being addressed for future improvement.
Opportunities lie in acquisitions, FDA approvals, and strategic commercial initiatives for growth and margin expansion.

Boston Scientific (BSX) exceeds Q4 expectations, eyes growth opportunities

Boston Scientific (BSX) reported impressive Q4 2023 results, exceeding sales and EPS guidance.
The company showcased strong regional growth, highlighted key products, and outlined solid 2024 outlook.
While facing challenges like delayed product launches and market disruptions, BSX remains focused on growth opportunities.
Strategic acquisitions and margin improvement initiatives position Boston Scientific for continued success in the future.

Boston Scientific beats Q1 expectations, eyes growth in key markets

Boston Scientific delivered strong Q1 results, exceeding expectations and showcasing growth across key regions and business units.
While facing challenges like inventory charges, the company is focused on leveraging opportunities in expanding product indications and enhancing capabilities.
With raised full-year guidance and a focus on innovation and market expansion, Boston Scientific is poised for continued growth and success in 2024.

Boston Scientific (BSX) reports stellar Q2 results and eyes sustained growth

Boston Scientific's Q2 2024 performance exceeded expectations, showcasing strong financial results and regional sales growth across key markets.
The company's strategic strengths lie in diversified business units, innovative products like FARAPULSE, and strategic acquisitions like Silk Road Medical.
While challenges exist in adoption metrics and margin expansion, BSX's focus on reinvestment and growth opportunities position it well for sustained success.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities in Asia

Boston Scientific's Q3 performance exceeded expectations, driven by strong sales growth and increased adjusted EPS.
The company's focus on innovation and strategic investments in key business units like Cardiology and Neuromodulation bode well for future growth.
Despite challenges in China and the need to deliver on growth targets, Boston Scientific remains confident in its ability to sustain top-tier financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Data from first coronary DCB study in U.S. meet 12-month primary endpoint, demonstrate low adverse event rates with AGENT DCB MARLBOROUGH, Mass. and SAN FRANCISCO , Oct. 25, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month results from the pivotal AGENT IDE clinical trial of the AGENT™ Drug-Coated Balloon (DCB).1 Primary endpoint findings from this first clinical trial in the U.S. to evaluate the safety and effectiveness of using a DCB to treat coronary in-stent restenosis (ISR) were presented in a late-breaking clinical trial session at Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation.

Boston Scientific AGENT™ Drug-Coated Balloon Demonstrates Superiority to Uncoated Balloon Angioplasty in the AGENT IDE Trial

Boston Scientific's quarterly results on Thursday are likely to show the benefits of a rebound in elective procedures and help ease fears that the medical device maker could take a hit from the surging popularity of weight-loss drugs.

Boston Scientific may be shielded from weight-loss drugs hit by procedure recovery

Analysis is first to compare health system-based electronic health record data for treatment of pulmonary embolism with interventional devices MARLBOROUGH, Mass. , Oct. 24, 2023 /PRNewswire/ -- Data from the REAL-PE study was presented today at Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, demonstrating that patients treated for pulmonary embolism (PE) with the Boston Scientific (NYSE: BSX) EKOS™ Endovascular System (EKOS) had lower rates of adverse events, including statistically significant lower rates of major bleeding, within seven days following their procedure compared to the Inari FlowTriever® System.

REAL-PE Study Demonstrates Statistically Significant Lower Major Bleeding Rates with the EKOS™ Endovascular System Compared to Mechanical Thrombectomy Device for Treatment of Pulmonary Embolism

With global staffing issues and the supply situation gradually improving, Boston Scientific's (BSX) international business is expected to have improved further in the third quarter.

What's in Store for Boston Scientific (BSX) in Q3 Earnings?

Lennar

Paychex

One tool that investors can easily access for any stock is analyst ratings. These ratings point you in the direction of stocks to buy and stocks to sell.

The Pros Got It Wrong: 3 Stocks to Sell Despite Recent Upgrades

Boston Scientific (BSX) receives the FDA's nod for an expanded indication of Wavewriter SCS Systems.

Boston Scientific's (BSX) Wavewriter Alpha SCS Gets FDA's Nod

MGM Resorts

Given its better prospects, we believe MGM Resorts stock (NYSE: MGM) is a better pick than Boston Scientific stock (NYSE: BSX).

Should You Pick MGM Resorts Over Boston Scientific Stock For Better Returns?

Haemonetics

Insulet

Stryker

Zimmer Biomet Hlds

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, BSX, ZBH, PODD and HAE are well-poised to gain from the favorable factors.

5 Medical Product Stocks to Buy Amid Industry Recovery

CareTrust REIT

Exact Sciences

Life Time Group Holdings

Topgolf Callaway Brands Corp

Novo Nordisk

Royal Caribbean Cruises

There's no doubt that America is aging. The numbers do not lie.

7 Affordable Stocks to Invest in as America's Population Ages

Fresenius Medical Care

Baxter

Intuitive Surgical

The trial success of Novo Nordisk's hit drug against kidney failure sent shares of a German kidney dialysis services firm plummeting on Wednesday.

Dialysis company shares plunge after Ozempic trial success vs. kidney trouble

MARLBOROUGH, Mass. , Oct. 2, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ending September 30, 2023, on Thursday, October 26, 2023, at 8:00 a.m.

Boston Scientific Announces Conference Call Discussing Third Quarter 2023 Results

DraftKings

Wynn Resorts

The bank has updated its Focus List, the compilation of its analysts' top ideas. These three shares could help a portfolio rebound.

Stock Plays for October: 3 to Watch, According to J.P. Morgan

Boston Scientific's (BSX) new M&A deal is likely to broaden the Neuromodulation business portfolio.

Boston Scientific (BSX) Set to Acquire Relievant Medsystems

CVS Health

WOONSOCKET, R.I. , Sept. 21, 2023 /PRNewswire/ -- CVS Health Corporation (NYSE: CVS) has appointed Michael F.

CVS Health appoints Michael F. Mahoney to its Board of Directors

Boston Scientific kicked off its Investor Day on Wednesday, a day after announcing its Relievant buyout, and BSX stock jumped.

Boston Scientific Briefly Launches Into Buy Zone, But Investor Day Hype Cools

Apple

Colgate-Palmolive

Costco

Monster Beverage

UnitedHealth Group

Apple, Boston Scientific, Costco, Monster Beverage, UnitedHealth, and Colgate-Palmolive shares could still rise in the face of a consumer-spending slump, says Morgan Stanley.

6 Growth Stocks That Look Recession-Resistant, According to Morgan Stanley

Boston Scientific Corp. BSX, +0.19% said Tuesday it has entered an agreement to acquire Relievant Medsystems Inc., a privately held medical tech company that has developed a treatment for a form of chronic low back pain. Boston Scientific will pay $850 million upfront and additional but undisclosed contingent payments based on reaching certain sales goals over the next three years.

Boston Scientific to acquire Relievant Medsystems for $850 million upfront, plus milestone payments

Boston Scientific said on Tuesday it would buy private medical tech company Relievant Medsystems for an upfront cash payment of $850 million.

Boston Scientific to pay $850 mln upfront to buy Relievant Medsystems

Acquisition intended to expand neuromodulation portfolio to provide more treatment options for people living with chronic low back pain MARLBOROUGH, Mass. , Sept. 19, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the Intracept® Intraosseous Nerve Ablation System to treat vertebrogenic pain, a form of chronic low back pain.

Boston Scientific Announces Agreement to Acquire Relievant Medsystems, Inc.

Accenture Plc

AutoZone

BioMarin Pharmaceutical

Investors stumped as to where the U.S. economy is situated in the current business cycle, should be focusing on late-cycle stock sectors, which includes one that has been heating up of late.

Investors should stick to the ‘late cycle playbook' and buy these sectors, says Morgan Stanley's Mike Wilson

Altria

We believe that Boston Scientific stock (NYSE: BSX) is a better pick over Altria stock (NYSE: MO), given its better prospects.

Is Boston Scientific A Better Pick Over Altria Stock?

Boston Scientific's (BSX) latest device features a polymer coating, visualization markers and a broader size matrix to treat a wider range of patients.

Boston Scientific (BSX) WATCHMAN FLX Pro Gets FDA Approval

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass. , Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration approval for the latest-generation WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device.

Boston Scientific Announces FDA Approval for the Latest-Generation WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device

MARLBOROUGH, Mass. , Sept. 5, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Wednesday, September 20, 2023, between 8:30 a.m.

Boston Scientific Announces 2023 Investor Day Meeting and Conference Call Discussing Third Quarter 2023 Results

Boston Scientific's (BSX) FARAPULSE PFA System's performance in the trial is an encouraging sign of the potential utilization of the device in the United States.

News for Boston Scientific Stock (BSX)